Central Cancer Registry Reporting Content IG
1.0.0 - STU 1 United States of America flag

This page is part of the Making EHR Data MOre available for Research and Public Health (MedMorph) Central Cancer Registry Reporting Content IG (v1.0.0: STU1) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

: Cancer Related Medication Administration - Example - XML Representation

Raw xml | Download



<MedicationAdministration xmlns="http://hl7.org/fhir">
  <id value="cancer-related-medication-administration-example"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Narrative</b></p><p><b>status:</b> completed</p><p><b>category:</b> Outpatient</p><p><b>medication:</b> rxnorm 1790099 doxorubicin hydrochloride 20 MG per 10 ML Injection</p><p><b>subject:</b> Amy Shaw</p><p><b>effective:</b> 2018-04-22</p><p><b>Performer:</b> Joseph Nichols</p><p><b>reasonReference:</b> Condition-primary-cancer-condition-breast</p><p><b>authoredOn:</b> 2018-04-12</p><p><b>note:</b> doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects.</p><p><b>Route:</b> SNOMED 47625008 Intravenous route (qualifier value)</p><p><b>Dose:</b> 105.96 mg</p></div>
  </text>
  <status value="completed"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/medication-admin-category"/>
      <code value="outpatient"/>
    </coding>
  </category>
  <medicationCodeableConcept>
    <coding>
      <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
      <code value="1790099"/>
      <display value="10 ML doxorubicin hydrochloride 2 MG/ML Injection"/>
    </coding>
  </medicationCodeableConcept>
  <subject>🔗 
    <reference value="Patient/example"/>
  </subject>
  <effectiveDateTime value="2018-04-22"/>
  <performer>
    <actor>🔗 
      <reference value="Practitioner/1"/>
    </actor>
  </performer>
  <reasonReference>🔗 
    <reference value="Condition/primary-cancer-condition-breast"/>
  </reasonReference>
  <note>
    <authorReference>🔗 
      <reference value="Practitioner/1"/>
    </authorReference>
    <time value="2018-04-22"/>
    <text
          value="doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."/>
  </note>
  <dosage>
    <route>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="47625008"/>
        <display value="Intravenous route (qualifier value)"/>
      </coding>
    </route>
    <dose>
      <value value="105.96"/>
      <unit value="mg"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="mg"/>
    </dose>
  </dosage>
</MedicationAdministration>